Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Abstract Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC. Thirty patients with pathologically confirmed advanced ICC re...

Full description

Bibliographic Details
Main Authors: Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Hui-Chuan Sun, Fei Liang, Yuan Ji, Yi Chen, Guo-Huan Yang, Jia-Cheng Lu, Xian-Long Meng, Xin-Ying Wang, Lei Sun, Ning-Ling Ge, Xiao-Wu Huang, Shuang-Jian Qiu, Xin-Rong Yang, Qiang Gao, Yi-Feng He, Yang Xu, Jian Sun, Zheng-Gang Ren, Jia Fan, Jian Zhou
Format: Article
Language:English
Published: Nature Publishing Group 2023-03-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01317-7

Similar Items

Similar Items